Zetia Clinical Trials and Research Studies

All Categories Medications / Interventions » Zetia

A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)

Condition: Dyslipidemia
Interventions: Drug: Ezetimibe/simvastatin; Drug: Other Statin
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012
Sitosterolemia Metabolism

Condition: Sitosterolemia
Intervention: Drug: Ezetimibe
Sponsors: University of Manitoba; University of Manitoba
Recruiting - verified April 2012
Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.

Condition: Hypercholesterolaemia
Interventions: Drug: 10mg Ezetimibe; Drug: 10 mg Ezetimibe - wash out period
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012
Vytorin in the Treatment of Alopecia Areata

Condition: Alopecia Areata
Interventions: Drug: vytorin; Drug: vytorin
Sponsors: University of Miami; University of Miami
Recruiting - verified January 2012
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.

Condition: Cardiovascular Diseases
Interventions: Drug: AMR101; Drug: Placebo
Sponsors: Amarin Pharma Inc.; Amarin Pharma Inc.
Recruiting - verified March 2012
Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients

Condition: Coronary Artery Disease
Interventions: Drug: Ezetimibe; Drug: Nutraceuticals
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Not yet recruiting - verified December 2011
Pattern of Statins Use in Catalonia

Condition: Hypercholesteremia
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Completed - verified February 2012
Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe

Conditions: Type 2 Diabetes; Inflammation
Interventions: Drug: Simvastatin 80 mg; Drug: Sim10/Eze10; Drug: Placebo
Sponsors: University of Heidelberg; University of Heidelberg
Completed - verified August 2011
Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Conditions: Hypercholesterolemia; Dyslipidemia
Interventions: Drug: Rosuvastatin + Ezetimibe; Drug: Simvastatin + Ezetimibe
Sponsors: Ache Laboratorios Farmaceuticos S.A.; Ache Laboratorios Farmaceuticos S.A.
Not yet recruiting - verified August 2011
A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)

Conditions: Dyslipidemia; Hypercholesterolemia
Intervention:
Sponsors: Merck; Merck
Active, not recruiting - verified September 2011
Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.

Condition: ST-Segment Elevation Myocardial Infarction
Interventions: Drug: Ezetimibe; Drug: Placebo
Sponsors: Odense University Hospital; Odense University Hospital
Recruiting - verified June 2011
Effect of Ezetimibe or Simvastatin or Both on LDL-Subfractions in Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus Type 2; Hypercholesterolemia
Interventions: Drug: ezetimibe; Drug: simvastatin; Drug: Ezetimibe 10/Simvastatin 20
Sponsors: University Hospital Freiburg; University Hospital Freiburg; Essex Pharma GmbH
Completed - verified February 2008
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)

Condition: Hypercholesterolemia
Intervention: Drug: Ezetimibe
Sponsors: Merck; Merck
Completed - verified February 2012
Study to Assess the Tolerability and Efficacy of AMG 145 in Patients With Hypercholesterolemia Unable to Tolerate an Effective Dose of a Statin.

Condition: Hyperlipidemia
Interventions: Biological: AMG 145; Other: Ezetimibe; Other: Placebo
Sponsors: Amgen; Amgen
Active, not recruiting - verified April 2012
Study to Assess the Tolerability and Efficacy of AMG 145 Monotherapy in Patients With Hypercholesterolemia

Condition: Hyperlipidemia
Interventions: Biological: AMG 145; Other: Ezetimibe; Other: Placebo
Sponsors: Amgen; Amgen
Active, not recruiting - verified April 2012
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

Condition: Hypercholesterolemia
Interventions: Drug: Atorvastatin; Drug: Ezetimibe; Drug: Ezetimibe/atorvastatin; Drug: Placebo to atorvastatin; Drug: Placebo to ezetimibe; Drug: Placebo to ezetimibe/atorvastatin
Sponsors: Merck; Merck
Completed - verified May 2012
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

Condition: Hypercholesterolemia
Interventions: Drug: Atorvastatin; Drug: Ezetimibe; Drug: Ezetimibe/atorvastatin; Drug: Placebo to atorvastatin; Drug: Placebo to ezetimibe; Drug: Placebo to ezetimibe/atorvastatin
Sponsors: Merck; Merck
Active, not recruiting - verified April 2012